Day: February 17, 2026

COMPANY ANNOUNCEMENT NO. 11-2026FLSmidth & Co. A/S17 February 2026Copenhagen, DenmarkFLSmidth & Co. A/S (“FLSmidth”) today announces the intention to initiate a new share buy-back programme of up to DKK 1.0 billion after the release of its Q1 2026 financial results. The company’s intention to initiate a share buy-back programme is supported by a solid balance sheet, sound cash-flow generation and the expected net cash proceeds from the sale of the company’s former corporate headquarters totalling DKK 730 million (ref. Company Announcement no. 9-2025), expected to be received upon closing of the transaction at the end of the first quarter of 2026. While pursuing value-accretive investments remains an important strategic focus point for FLSmidth, the company continues to prudently balance additional investments in growth with...

WALTHAM, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) — Crane NXT, Co. (NYSE: CXT), a premier industrial technology company, announced that it will webcast its 2026 Investor Day presentations from 8:30 a.m. to approximately 12:00 p.m. Eastern Time on Wednesday, February 25, 2026. Investors who have not yet registered and are interested in attending the event in New York City, should contact Matt Roache, Vice President, Investor Relations, for additional details. The event will feature presentations from the following members of Crane NXT’s management team:Aaron Saak, President and Chief Executive Officer Sam Keayes, Senior Vice President, Security and Authentication Technologies Michael Mahan, President, CPI Christina Cristiano, Senior Vice President, Chief Financial OfficerFollowing the presentations, in-person attendees will have...

CHASKA, Minn., Feb. 17, 2026 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at DCAT Week 2026. The conference will take place March 23-26, 2026, in New York City. Details regarding Lifecore’s participation are as follows:DCAT Week 2026Details: Lifecore team will host customers and prospective partners to discuss development and manufacturing solutions for existing and new injectable programs. Conference Dates: March 23-26, 2026Location: New York, NYIf you are interested in meeting with Lifecore during DCAT week, please reach out to us at: cdmo@lifecore.com. About Lifecore Biomedical Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development...

ANN ARBOR, Mich., Feb. 17, 2026 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced that its 2026 production plan has officially moved from strategy to execution. The Company has now moved bio-material to incubation, getting a jumpstart on its March production plan and formally initiating its multi-ton spider silk scale-up initiative. This milestone follows Kraig’s recently announced 2026 production schedule. This aggressive plan is set to achieve sustained monthly production of recombinant spider silk cocoons at unprecedented commercial volumes. With the release of the first wave of production materials now complete, Kraig Labs has activated its expanded manufacturing...

Gilat Defense will deliver advanced modems to support and scale secure, mission-critical satellite communications for defense operations  PETAH TIKVA, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services, announced today that its defense division, Gilat Defense, has been awarded a contract valued $9 million by Israel’s Ministry of Defense for the delivery and integration of satellite communication systems and services. The order includes next generation defense modems which are a key component of Gilat’s ground system Defense solution. These modems will significantly enhance the system’s ability to deliver secure, reliable, and flexible communications. Built for mission-critical operations, they are engineered...

– Virtual presentation scheduled for Thursday, February 26, 2026, at 4:00 PM ET –– Webcast may be accessed here – MIAMI, Feb. 17, 2026 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the treatment of NF1-associated plexiform neurofibromas (NF1-PN), today announced that Chief Executive Officer Tiago Reis Marques will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held in a virtual format February 25–26, 2026. The Company’s presentation is scheduled for Thursday, Feb 26 at 4:00-4:30 PM ET in Track 2, and the webcast may be viewed here. In addition to the presentation, management will be available for one-on-one meetings with qualified members...